AnaptysBio Inc (NAS:ANAB)
$ 24.67 -0.25 (-1%) Market Cap: 673.95 Mil Enterprise Value: 343.78 Mil PE Ratio: 0 PB Ratio: 14.10 GF Score: 60/100

AnaptysBio Inc at JPMorgan Healthcare Conference Transcript

Jan 15, 2020 / 10:30PM GMT
Release Date Price: $15.51 (+3.30%)
Anupam Rama
JP Morgan Chase & Co, Research Division - VP and Analyst

Okay. We'll get started here. Welcome to the afternoon session of the 2020 J.P. Morgan Healthcare Conference Wednesday afternoon session.

My name is Anupam Rama, I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Matt Bannon and Tessa Romero from the team.

Our next presenting company is AnaptysBio. And presenting on behalf of the company, we have CEO Hamza Suria. Hamza?

Hamza Suria
AnaptysBio, Inc. - President, CEO & Director

Thank you, Anupam, and appreciate JPMorgan providing us an opportunity to present an update regarding AnaptysBio here. I will be making forward-looking statements regarding the company. We encourage you to review our SEC filings for relevant disclosures.

AnaptysBio is a clinical-stage novel antibody R&D engine. Our focus and our business model is to innovate first-in-class antibodies against emerging biology in immunology and drive those therapeutics from scratch generated internally to clinical development

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot